FDA warns about 'miracle' young blood infusion treatments

FDA warns about 'Miracle' young blood infusion treatments

(HealthDay)—The use of plasma infusion therapies (often called "vampire" treatments, in which people undergo infusions of a young donor's blood) is on the rise across the United States, often costing thousands of dollars per treatment, according to the U.S. Food and Drug Administration.

But these expensive "fountain of youth" therapies are unproven and potentially unsafe, the FDA warned on Tuesday. The service is being offered by businesses in many states to allegedly treat conditions ranging from normal aging and to serious disorders such as dementia, Parkinson disease, multiple sclerosis, Alzheimer disease, cardiovascular disease, and posttraumatic stress disorder.

"Simply put, we're concerned that some patients are being preyed upon by unscrupulous actors touting treatments of plasma from young donors as cures and remedies," FDA Commissioner Scott Gottlieb, M.D., said in an agency news release. "Such treatments have no proven clinical benefits for the uses for which these clinics are advertising them and are potentially harmful."

The FDA reminds both consumers and that treatments using plasma from young donors have not been proven to be either therapeutically beneficial or safe. Patients and are urged to report any related to treatment with plasma from young donors to the FDA MedWatch Adverse Event Reporting program.


Explore further

Blood-plasma infusions safe to be explored as Alzheimer's treatment

More information: More Information

Copyright © 2019 HealthDay. All rights reserved.

Citation: FDA warns about 'miracle' young blood infusion treatments (2019, February 20) retrieved 23 August 2019 from https://medicalxpress.com/news/2019-02-fda-miracle-young-blood-infusion.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more